Table 6.

Univariate regression logistic analysis of the risk of hospitalization due to decompensation of HF.

Group of factors	Factor	AF-HFpEF		AF-HFmrEF		AF-HFrEF
		OR (2.5–97.5)	p value	OR (2.5–97.5)	p value	OR (2.5–97.5)	p value
Laboratory tests	LDH	1.007 (1.004–1.011)	<0.001
	Total bilirubin	1.035 (1.005–1.07)	0.031
	Kreatinin					1.008 (1.002–1.014)	0.01
Demography	Age > 65 years	2.329 (1.462–3.745)	<0.001			1.736 (1.17–2.584)	0.006
	Female gender	1.866 (1.198–2.921)	0.006
Habits and lifestyle	Smoking (ever)	1.852 (1.073–3.236)	0.028
	Bad habits	2.009 (1.107–3.723)	0.023
	Alcohol usage history					1.37 (1.038–1.828)	0.028
	Level of physical activity			0.549 (0.274–1.081)	0.085	0.616 (0.399–0.944)	0.027
Symptoms and syndromes	The number of specific signs of HF	1.482 (1.146–1.946)	0.003
	Increase of venous pressure					2.383 (1.02–5.847)	0.048
	The number of typical symptoms of HF					2.275 (1.1–4.844)	0.028
Concomitant diseases	Diabetes mellitus	1.733 (1.048–2.908)	0.034
CV system characteristics	Arterial hypertension					2.347 (1.524–3.663)	<0.001
	Duration of arterial hypertension	1.03 (1.002–1.061)	0.044
	Degree of tricuspid insufficiency	1.408 (1.027–1.949)	0.036
	Degree of aortal insufficiency	1.721 (1.074–2.865)	0.028
	Degree of pulmonary insufficiency	3.69 (1.46–10.87)	0.01
	Mitral insufficiency					1.543 (0.937–2.54)	0.087
	Hemodynamically significant coronary artery stenosis					2.166 (1.276–3.8)	0.005
	Cardiothoracic index (%)					1.138 (1.047–1.244)	0.003
	Vascular disease	1.73 (1.126–2.673)	0.013
	Prior stroke or TIA or thromboembolism	1.866 (1.198–2.921)	0.006
Therapy	Regular use of antiarrhythmic drugs	0.622 (0.393–0.978)	0.041
	Regular use of ACE inhibitors	0.582 (0.371–0.907)	0.017
	Permanent AF therapy with calcium channel blockers	0.505 (0.311–0.812)	0.005
	Regular use of angiotensin II receptor blocker	0.466 (0.288–0.745)	0.002			0.587 (0.331–1.01)	0.06
	Regular use of anticoagulants					0.389 (0.257–0.587)	<0.001
	Permanent AF therapy with beta-blockers					0.279 (0.152–0.496)	<0.001
	Rational therapy of HF					0.409 (0.271–0.611)	<0.001
	Regular use of aldosterone antagonist					0.584 (0.361–0.942)	0.027
	Regular use of NOAC					0.588 (0.377–0.907)	0.017
	Rate control strategy (versus rhythm control strategy)	1.779 (1.156–2.747)	0.009			0.283 (0.125–0.599)	0.001
AF/HF features	HF developed after AF debut	2.002 (1.049–3.879)	0.037
	AF duration	1.005 (1.001–1.01)	0.022
	HF duration					1.005 (1.002–1.009)	0.003
	EF					0.958 (0.922–0.995)	0.026
	Persistent form of AF (versus paroxysmal form)	0.464 (0.296–0.722	0.001			2.755 (1.451–5.405)	0.002
Scales and risks	CHA2DS2-VASc	1.393 (1.215–1.608)	<0.001	1.191 (0.981–1.46)	0.083	1.215 (1.089–1.359)	0.001
	HAS-BLED	1.461 (1.174–1.836)	0.001			1.196 (1.014–1.414)	0.035